Insuman Basal

Insulin human, the active ingredient in Insuman Basal, is an insulin presented as a solution for subcutaneous injection use. It treats diabetes mellitus in both type 1 and type 2 patients by providing basal insulin coverage to maintain stable blood glucose levels.

GNH USA supplies Insuman Basal as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance. The product meets EU standards and is distributed under strict temperature-controlled conditions to preserve potency.

Insuman Basal is a long‑acting insulin analogue used in the management of diabetes mellitus, acting on the basal glucose control pathway. - Type 1 diabetes mellitus: provides basal insulin to mimic physiologic secretion, helping maintain fasting glucose levels within target range. - Type 2 diabetes mellitus: supplements endogenous insulin production to achieve basal glycemic control, often in combination with oral antidiabetic agents. - Insulin‑dependent diabetes requiring basal coverage: used when basal insulin needs cannot be met by rapid‑acting formulations alone.

Insuman Basal may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypoglycemia: low blood glucose levels, especially if dosing is mismatched with food intake. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: gradual increase in body weight with prolonged insulin therapy. - Lipodystrophy: localized thickening or loss of subcutaneous fat at injection sites. - Headache: mild to moderate head discomfort. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Severe hypoglycemia: neurological symptoms such as seizures, loss of consciousness, or confusion requiring immediate assistance. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Insulin edema: fluid retention leading to peripheral swelling.

When using Insuman Basal, several precautions should be observed to ensure safety and efficacy. - Dose adjustment: tailor insulin dose based on blood glucose monitoring, diet, and activity level. - Hypoglycemia risk: educate patients to recognize and treat low blood sugar promptly. - Concomitant medications: review other drugs that may affect glucose levels, such as sulfonylureas. - Renal or hepatic impairment: monitor closely as insulin clearance may be altered. - Pregnancy and lactation: use only if benefits outweigh potential risks and under medical supervision. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Basal can interact with other medicines, influencing its glucose‑lowering effect or increasing adverse event risk.

Major Interactions (Avoid): - Sulfonylureas: combined use may cause severe hypoglycemia. - Meglitinides: additive glucose‑lowering effect raises hypoglycemia risk. - Beta‑blockers: may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely): - Corticosteroids: can increase blood glucose, requiring insulin dose adjustment. - Thiazide diuretics: may raise glucose levels, necessitating monitoring. - Oral contraceptives: may alter insulin requirements slightly. - ACE inhibitors: may enhance insulin sensitivity, monitor glucose.